These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 33478976

  • 1. Short-Duration Prednisolone in Children with Nephrotic Syndrome Relapse: A Noninferiority Randomized Controlled Trial.
    Kainth D, Hari P, Sinha A, Pandey S, Bagga A.
    Clin J Am Soc Nephrol; 2021 Feb 08; 16(2):225-232. PubMed ID: 33478976
    [Abstract] [Full Text] [Related]

  • 2. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
    Webb NJ, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, Trompeter RS, Cummins C, Wheatley K, Ives NJ.
    Health Technol Assess; 2019 May 08; 23(26):1-108. PubMed ID: 31156083
    [Abstract] [Full Text] [Related]

  • 3. Daily low-dose prednisolone to prevent relapse of steroid-sensitive nephrotic syndrome in children with an upper respiratory tract infection: PREDNOS2 RCT.
    Christian MT, Webb NJ, Woolley RL, Afentou N, Mehta S, Frew E, Brettell EA, Khan AR, Milford DV, Bockenhauer D, Saleem MA, Hall AS, Koziell A, Maxwell H, Hegde S, Finlay ER, Gilbert RD, Jones C, McKeever K, Cook W, Ives N.
    Health Technol Assess; 2022 Jan 08; 26(3):1-94. PubMed ID: 35060851
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of body weight vs body surface area-based prednisolone regimen in nephrotic syndrome.
    Basu B, Bhattacharyya S, Barua S, Naskar A, Roy B.
    Clin Exp Nephrol; 2020 Jul 08; 24(7):622-629. PubMed ID: 32201918
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of low-dose daily versus alternate-day prednisolone in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.
    Yadav M, Sinha A, Khandelwal P, Hari P, Bagga A.
    Pediatr Nephrol; 2019 May 08; 34(5):829-835. PubMed ID: 30194663
    [Abstract] [Full Text] [Related]

  • 6. Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial).
    Hama T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Sako M, Saito-Oba M, Nozu K, Shima Y, Iijima K, Yoshikawa N, Japanese Study Group of Kidney Disease in Children (JSKDC).
    BMC Nephrol; 2018 Sep 10; 19(1):223. PubMed ID: 30200895
    [Abstract] [Full Text] [Related]

  • 7. An open label non-inferiority randomized controlled trial evaluated alternate day prednisolone given daily during infections vs. levamisole in frequently relapsing nephrotic syndrome.
    Sinha A, Devi KG, Kalra S, Mani K, Hari P, Bagga A.
    Kidney Int; 2024 May 10; 105(5):1113-1123. PubMed ID: 38360110
    [Abstract] [Full Text] [Related]

  • 8. Use of a low-dose prednisolone regimen to treat a relapse of steroid-sensitive nephrotic syndrome in children.
    Raja K, Parikh A, Webb H, Hothi D.
    Pediatr Nephrol; 2017 Jan 10; 32(1):99-105. PubMed ID: 27677978
    [Abstract] [Full Text] [Related]

  • 9. Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation.
    Webb NJA, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, Trompeter RS, Cummins C, Deeks JJ, Wheatley K, Ives NJ, PREDNOS Collaborative Group.
    BMJ; 2019 May 23; 365():l1800. PubMed ID: 31335316
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.
    Sinha A, Puraswani M, Kalaivani M, Goyal P, Hari P, Bagga A.
    Kidney Int; 2019 Jan 23; 95(1):210-218. PubMed ID: 30497684
    [Abstract] [Full Text] [Related]

  • 11. REducing STEroids in Relapsing Nephrotic syndrome: the RESTERN study- protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study.
    Schijvens AM, Dorresteijn EM, Roeleveld N, Ter Heine R, van Wijk JAE, Bouts AHM, Keijzer-Veen MG, van de Kar NCAJ, van den Heuvel LPWJ, Schreuder MF.
    BMJ Open; 2017 Sep 27; 7(9):e018148. PubMed ID: 28963315
    [Abstract] [Full Text] [Related]

  • 12. Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome.
    Ekka BK, Bagga A, Srivastava RN.
    Pediatr Nephrol; 1997 Oct 27; 11(5):597-9. PubMed ID: 9323286
    [Abstract] [Full Text] [Related]

  • 13. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome.
    Sinha A, Saha A, Kumar M, Sharma S, Afzal K, Mehta A, Kalaivani M, Hari P, Bagga A.
    Kidney Int; 2015 Jan 27; 87(1):217-24. PubMed ID: 25029428
    [Abstract] [Full Text] [Related]

  • 14. A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children.
    Hiraoka M, Tsukahara H, Matsubara K, Tsurusawa M, Takeda N, Haruki S, Hayashi S, Ohta K, Momoi T, Ohshima Y, Suganuma N, Mayumi M, West Japan Cooperative Study Group of Kidney Disease in Children.
    Am J Kidney Dis; 2003 Jun 27; 41(6):1155-62. PubMed ID: 12776266
    [Abstract] [Full Text] [Related]

  • 15. Low-dose versus conventional-dose prednisolone for nephrotic syndrome relapses: a randomized controlled non-inferiority trial.
    Sheikh S, Mishra K, Kumar M.
    Pediatr Nephrol; 2021 Oct 27; 36(10):3143-3150. PubMed ID: 33861375
    [Abstract] [Full Text] [Related]

  • 16. Two-year outcome of the ISKDC regimen and frequent-relapsing risk in children with idiopathic nephrotic syndrome.
    Nakanishi K, Iijima K, Ishikura K, Hataya H, Nakazato H, Sasaki S, Honda M, Yoshikawa N, Japanese Study Group of Renal Disease in Children.
    Clin J Am Soc Nephrol; 2013 May 27; 8(5):756-62. PubMed ID: 23371961
    [Abstract] [Full Text] [Related]

  • 17. Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial.
    Gulati A, Sinha A, Sreenivas V, Math A, Hari P, Bagga A.
    Clin J Am Soc Nephrol; 2011 Jan 27; 6(1):63-9. PubMed ID: 20847092
    [Abstract] [Full Text] [Related]

  • 18. Adrenocorticotropic Hormone for Childhood Nephrotic Syndrome: The ATLANTIS Randomized Trial.
    Wang CS, Travers C, McCracken C, Leong T, Gbadegesin R, Quiroga A, Benfield MR, Hidalgo G, Srivastava T, Lo M, Yadin O, Mathias R, Araya CE, Khalid M, Orjuela A, Zaritsky J, Al-Akash S, Kamel M, Greenbaum LA.
    Clin J Am Soc Nephrol; 2018 Dec 07; 13(12):1859-1865. PubMed ID: 30442868
    [Abstract] [Full Text] [Related]

  • 19. Steroid treatment for the first episode of childhood nephrotic syndrome: comparison of the 8 and 12 weeks regimen using an individual patient data meta-analysis.
    Schijvens AM, Teeninga N, Dorresteijn EM, Teerenstra S, Webb NJ, Schreuder MF.
    Eur J Pediatr; 2021 Sep 07; 180(9):2849-2859. PubMed ID: 33774744
    [Abstract] [Full Text] [Related]

  • 20. Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome.
    Basu B, Preussler S, Sander A, Mahapatra TKS, Schaefer F.
    BMC Nephrol; 2020 Nov 30; 21(1):520. PubMed ID: 33256621
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.